Biocept (FRA:B00) Retained Earnings : €-285.40 Mil (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Biocept Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Biocept's retained earnings for the quarter that ended in Jun. 2023 was €-285.40 Mil.

Biocept's quarterly retained earnings declined from Dec. 2022 (€-281.73 Mil) to Mar. 2023 (€-285.41 Mil) but then increased from Mar. 2023 (€-285.41 Mil) to Jun. 2023 (€-285.40 Mil).

Biocept's annual retained earnings declined from Dec. 2020 (€-216.62 Mil) to Dec. 2021 (€-235.72 Mil) and declined from Dec. 2021 (€-235.72 Mil) to Dec. 2022 (€-281.73 Mil).

Biocept Retained Earnings Historical Data

The historical data trend for Biocept's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocept Retained Earnings Chart

Biocept Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Retained Earnings

Get a 7-Day Free Trial

-193.78

-221.15

-216.62

-235.72

-281.73

Biocept Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Retained Earnings	Get a 7-Day Free Trial															-259.56	-282.72	-281.73	-285.41	-285.40

Biocept Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Biocept (FRA:B00) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Biocept (FRA:B00) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (FRA:B00) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

BIOCQ:USA

Address

9955 Mesa Rim Road, San Diego, CA, USA, 92121

Website

https://www.biocept.com

Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Biocept (FRA:B00) Headlines

No Headlines